Bharat Biotech International Ltd (BBIL) has established India’s first vertically integrated, purpose-built Cell & Gene Therapy (C&GT) and Viral Vector Production facility at Genome Valley, Hyderabad, with an investment of $75 million.

The new facility marks Bharat Biotech’s expansion beyond vaccines into cutting-edge regenerative and personalized therapies. “With this, we are moving beyond vaccine innovation to pioneering advanced therapies that offer hope to millions,” said Krishan Ella, Executive Chairman of Bharat Biotech, at the facility’s inauguration. He emphasized the need for a conducive regulatory framework to foster research and innovation in the segment.

According to Raches Ella, Chief Development Officer leading the CGT initiative, the facility is designed to produce high-titer viral vectors—AAV, Lentivirus, and Adenovirus—critical for cell and gene therapy applications. These vectors play a key role in treating cancer, genetic disorders, and other life-threatening diseases. Additionally, the facility has the capability to manufacture platform products targeting blood cancers, solid tumors, and rare genetic conditions.

The high cost of cell and gene therapies, currently around ₹50 lakh per treatment, is expected to reduce with indigenous production, making these therapies more accessible. Bharat Biotech has five pipeline products—two in cell culture and three in gene therapy—with the first expected to launch upon successful clinical trials and regulatory approvals.

The company has also partnered with the University of Wisconsin-Madison for research collaboration, which could expand into commercial agreements, including in-licensing. Bharat Biotech is also exploring export potential and opportunities in medical tourism for its advanced therapies.

Oncology and rare disease treatments will be key focus areas, with the facility supporting next-generation therapies like CD19 CAR T-cell therapy for blood cancers and gene therapy for inherited disorders. Scientist Krishanu Saha from the University of Wisconsin-Madison highlighted the role of AI-driven innovation in developing next-generation CAR cell therapies, which could revolutionize patient care worldwide.

Spanning 50,000 sq ft, the state-of-the-art CGT facility is GMP-certified and equipped with a clean room setup, positioning Bharat Biotech at the forefront of advanced medical treatments. By addressing critical unmet clinical needs, the company aims to drive innovation in the global cell and gene therapy landscape.